FOXO4-DRI

PEPTIDES+ MEMBERS ONLY

INDICATIONS FOR USE

FOXO4-DRI is an experimental peptide used in anti-aging research. Its proposed application is to selectively target senescent cells, thereby improving tissue function and reducing age-related inflammation.

ROUTE OF ADMINISTRATION

  • Subcutaneous injection.

COMMON INITIAL DOSING REGIMENS

  • Inject 0.3mg-0.5mg (30-50 units via insulin syringe) SQ daily for 7 days, every other week.

MECHANISM OF ACTION

  • FOXO4-DRI inhibits the interaction between FOXO4 and p53 in senescent cells. By disrupting this interaction, senescent cells undergo apoptosis, thereby reducing cellular senescence and its associated pro-inflammatory secretory phenotype.

COMMON SIDE EFFECTS

  • Due to its experimental status, side effects in humans are largely unknown. Potential risks include:

  • Immune: Injection site reactions or systemic immune activation.

  • Metabolic: Possible off-target effects leading to fatigue or loss of appetite.

  • Rare: Theoretical risks include unintended apoptosis in non-senescent cells, leading to tissue damage.

CONTRAINDICATIONS

  • Absolute: Hypersensitivity to the peptide or its components.

  • Relative: Use cautiously in patients with active infections, autoimmune diseases, or ongoing malignancies, as effects on the immune system are not fully understood.

DISCLAIMER

  • This medication is experimental and not FDA-approved.

MORE INFORMATION

  • FDA Safety Data Sheet not available (experimental peptide).

  • Li Y. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Exp Gerontol. 2024 [PubMed Link]

  • Kong YX. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025 [PubMed Link]

  • Zhang C. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020 [PubMed Link]

  • Born E. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023 [PubMed Link]

  • Huang Y. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021 [PubMed Link]

  • Bourgeois B. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025 [PubMed Link]

  • Meng J. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis. JCI Insight. 2021 [PubMed Link]

  • Valentijn FA. Cellular senescence in the aging and diseased kidney. J Cell Commun Signal. 2018 [PubMed Link]

  • van Willigenburg H. Cellular senescence as a therapeutic target to improve renal transplantation outcome. Pharmacol Res. 2018 [PubMed Link]

  • Krimpenfort P. Rejuvenation by Therapeutic Elimination of Senescent Cells. Cell. 2017 [PubMed Link]